Vir Biotechnology, Inc. Cash and Restricted Cash
Vir Biotechnology, Inc. (VIR) had Cash and Restricted Cash of $287.60 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-05
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $287.60M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $283.04M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $241.07M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $179.26M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $287.60M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $283.04M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $241.07M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $179.26M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $306.28M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $368.00M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $318.69M 10-Q · filed 2026-08-05 |
| 2024-09-30 | $264.33M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $317.18M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $180.47M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $261.29M 10-K · filed 2026-02-23 |
| 2023-09-30 | $472.35M 10-Q · filed 2024-11-04 |
| 2023-06-30 | $686.86M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $842.61M 10-Q · filed 2024-05-03 |
| 2022-12-31 | $867.97M 10-K · filed 2026-02-23 |
| 2022-09-30 | $983.97M 10-Q · filed 2023-11-03 |
| 2022-06-30 | $1.53B 10-Q · filed 2023-08-04 |
| 2022-03-31 | $835.80M 10-Q · filed 2023-05-08 |
| 2021-12-31 | $363.42M 10-K · filed 2025-02-27 |
| 2021-09-30 | $727.63M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $755.96M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $537.00M 10-Q · filed 2022-05-05 |
| 2020-12-31 | $451.49M 10-K · filed 2024-02-26 |
| 2020-09-30 | $473.08M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $384.00M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $178.71M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $122.82M 10-K · filed 2023-02-28 |
| 2019-09-30 | $105.37M 10-Q · filed 2020-11-10 |
| 2019-06-30 | $93.30M 10-Q · filed 2020-08-11 |
| 2019-03-31 | $73.12M 10-Q · filed 2020-05-12 |
| 2018-12-31 | $59.36M 10-K · filed 2022-02-28 |
| 2018-09-30 | $62.33M 10-Q · filed 2019-11-19 |
| 2017-12-31 | $188.92M 10-K · filed 2021-02-25 |
| 2016-12-31 | $14.11M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |